UV-4B 30 mg oral solution + UV-4B 75 mg oral solution + UV-4B 150 mg oral solution + UV-4B X mg (dose to be determined) oral solution + UV-4B Y mg (dose to be determined) oral solution + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Viral Infection
Conditions
Viral Infection
Trial Timeline
May 27, 2016 → Mar 2, 2017
NCT ID
NCT02696291About UV-4B 30 mg oral solution + UV-4B 75 mg oral solution + UV-4B 150 mg oral solution + UV-4B X mg (dose to be determined) oral solution + UV-4B Y mg (dose to be determined) oral solution + Placebo
UV-4B 30 mg oral solution + UV-4B 75 mg oral solution + UV-4B 150 mg oral solution + UV-4B X mg (dose to be determined) oral solution + UV-4B Y mg (dose to be determined) oral solution + Placebo is a phase 1 stage product being developed by Emergent BioSolutions for Viral Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT02696291. Target conditions include Viral Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02696291 | Phase 1 | Terminated |
Competing Products
17 competing products in Viral Infection